Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's flagship candidate, ACOG-100, seeks to improve cognitive function and tackle significant unmet needs among the aging demographic. With a robust proprietary neuroscience platform and a deep commitment to rigorous research and development, Alpha Cognition is well-positioned for growth as it advances its clinical pipeline and explores new therapeutic avenues. For institutional investors, the company presents a compelling opportunity to contribute to transformative patient care while capitalizing on the expanding healthcare sector.
| Revenue (TTM) | $15.26M |
| Gross Profit (TTM) | $14.13M |
| EBITDA | $-29.20M |
| Operating Margin | -127.30% |
| Return on Equity | -55.90% |
| Return on Assets | -33.50% |
| Revenue/Share (TTM) | $0.74 |
| Book Value | $2.87 |
| Price-to-Book | 5.04 |
| Price-to-Sales (TTM) | 12.61 |
| EV/Revenue | 10.4 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 267.60% |
| Shares Outstanding | $21.77M |
| Float | $11.62M |
| % Insiders | 5.28% |
| % Institutions | 53.32% |
Volatility is currently contracting
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation.
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial.
Alpha Cognition Inc. (ACOG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachu.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a mult.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced the top-line results from its BEACON real-world study evaluating provider-reported cognitive, behavioral, functional, and tolerability outcomes among long-term care residents with mild to moderate Alzheimer's disease who were receiv.
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACOG and any ticker you trade — then tracks every position and per-strategy win rate.
